Follow the people · Insider
Abraham Ceesay
Abraham Ceesay files insider transactions with the SEC as a chief executive officer of Rapport Therapeutics (RAPP). We hold 8 disclosed purchases and sales filed since 19 January 2018, 6 of them in the last 90 days.
- Files forRAPP
- Disclosed buys and sells8 in all, 6 in the last 90 days
- Last disclosure26 August 2026
Positions held
5 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 6 June 2024 — 25 August 2026Chief Executive Officer · Rapport Therapeutics (RAPP)46 Form 4 lines · source: SEC Form 4
- Filed 2 June 2025 — 8 May 2026Director · Charles River Laboratories International (CRL)3 Form 4 lines · source: SEC Form 4
- Filed 6 October 2023 — 4 September 2025Director · Pacira BioSciences (PCRX)6 Form 4 lines · source: SEC Form 4
- Filed 1 June 2021 — 6 February 2023President · Cerevel Therapeutics Holdings (CERE)20 Form 4 lines · source: SEC Form 4
- Filed 17 January 2018 — 17 January 2018Chief Operating Officer · scPharmaceuticals (SCPH)1 Form 4 line · source: SEC Form 4
Everything they disclosed
76 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 18,921 shares of Rapport TherapeuticsSEC Form 426 August 2026Common Stock · traded 25 August 2026 · filed 26 August 2026
- ▼ sold on the open market 14,171 shares of Rapport TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 8,370 shares of Rapport TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 3,664 shares of Rapport TherapeuticsSEC Form 412 August 2026Common Stock · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 19,500 shares of Rapport TherapeuticsSEC Form 412 August 2026Common Stock · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 5,794 shares of Rapport TherapeuticsSEC Form 412 August 2026Common Stock · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 2,203 shares of Rapport TherapeuticsSEC Form 429 July 2026Common Stock · traded 27 July 2026 · filed 29 July 2026
- ▼ sold on the open market 7 shares of Rapport TherapeuticsSEC Form 429 July 2026Common Stock · traded 27 July 2026 · filed 29 July 2026
- ▼ sold on the open market 5,481 shares of Rapport TherapeuticsSEC Form 415 July 2026Common Stock · traded 14 July 2026 · filed 15 July 2026
- ▼ sold on the open market 2,729 shares of Rapport TherapeuticsSEC Form 415 July 2026Common Stock · traded 14 July 2026 · filed 15 July 2026
- ▼ sold on the open market 7,344 shares of Rapport TherapeuticsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- ▼ sold on the open market 876 shares of Rapport TherapeuticsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- was granted 1,438 shares of Charles River Laboratories InternationalSEC Form 411 May 2026Common Stock · traded 8 May 2026 · filed 11 May 2026
- ▼ sold on the open market 3,552 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,281 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,983 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,100 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 3,552 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,281 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,983 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- ▼ sold on the open market 2,100 shares of Rapport TherapeuticsSEC Form 419 February 2026Common Stock · traded 18 February 2026 · filed 19 February 2026
- was granted 428,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to Buy) · traded 2 February 2026 · filed 4 February 2026
- was granted 428,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to Buy) · traded 2 February 2026 · filed 4 February 2026
- ▼ sold on the open market 5,833 shares of Rapport TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 5,083 shares of Rapport TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 5,833 shares of Rapport TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 5,083 shares of Rapport TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 2,441 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 2,792 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 600 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 2,147 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 2,421 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 515 shares of Rapport TherapeuticsSEC Form 418 December 2025Common Stock · traded 17 December 2025 · filed 18 December 2025
- ▼ sold on the open market 2,777 shares of Rapport TherapeuticsSEC Form 418 November 2025Common Stock · traded 17 November 2025 · filed 18 November 2025
- ▼ sold on the open market 3,056 shares of Rapport TherapeuticsSEC Form 418 November 2025Common Stock · traded 17 November 2025 · filed 18 November 2025
- ▼ sold on the open market 2,242 shares of Rapport TherapeuticsSEC Form 418 November 2025Common Stock · traded 17 November 2025 · filed 18 November 2025
- ▼ sold on the open market 2,841 shares of Rapport TherapeuticsSEC Form 418 November 2025Common Stock · traded 17 November 2025 · filed 18 November 2025
- ▼ sold on the open market 4,647 shares of Rapport TherapeuticsSEC Form 416 October 2025Common Stock · traded 15 October 2025 · filed 16 October 2025
- ▼ sold on the open market 1,186 shares of Rapport TherapeuticsSEC Form 416 October 2025Common Stock · traded 15 October 2025 · filed 16 October 2025
- ▼ sold on the open market 4,328 shares of Rapport TherapeuticsSEC Form 416 October 2025Common Stock · traded 15 October 2025 · filed 16 October 2025
- ▼ sold on the open market 755 shares of Rapport TherapeuticsSEC Form 416 October 2025Common Stock · traded 15 October 2025 · filed 16 October 2025
- ▼ sold on the open market 39,435 shares of Rapport TherapeuticsSEC Form 419 September 2025Common Stock · traded 17 September 2025 · filed 19 September 2025
- ▼ sold on the open market 1,400 shares of Rapport TherapeuticsSEC Form 419 September 2025Common Stock · traded 17 September 2025 · filed 19 September 2025
- ▼ sold on the open market 34,885 shares of Rapport TherapeuticsSEC Form 419 September 2025Common Stock · traded 17 September 2025 · filed 19 September 2025
- ▼ sold on the open market 700 shares of Rapport TherapeuticsSEC Form 419 September 2025Common Stock · traded 17 September 2025 · filed 19 September 2025
- ▼ sold on the open market 2,354 shares of Pacira BioSciencesSEC Form 48 September 2025Common Stock · traded 4 September 2025 · filed 8 September 2025
- was granted 11,279 shares of Pacira BioSciences (a derivative holding)SEC Form 413 June 2025Stock Option (Right to Buy) · traded 11 June 2025 · filed 13 June 2025
- was granted 6,163 shares of Pacira BioSciencesSEC Form 413 June 2025Common Stock · traded 11 June 2025 · filed 13 June 2025
- was granted 2,082 shares of Charles River Laboratories International (a derivative holding)SEC Form 44 June 2025Stock Options (Right to Buy) · traded 2 June 2025 · filed 4 June 2025
- was granted 946 shares of Charles River Laboratories InternationalSEC Form 44 June 2025Common Stock · traded 2 June 2025 · filed 4 June 2025
- was granted 428,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2025Stock Option (Right to Buy) · traded 3 February 2025 · filed 4 February 2025
- was granted 12,179 shares of Pacira BioSciences (a derivative holding)SEC Form 413 June 2024Stock Option (Right to Buy) · traded 12 June 2024 · filed 13 June 2024
- was granted 5,230 shares of Pacira BioSciencesSEC Form 413 June 2024Common Stock · traded 12 June 2024 · filed 13 June 2024
- was granted 530,647 shares of Rapport Therapeutics (a derivative holding)SEC Form 410 June 2024Stock Option (Right to Buy) · traded 6 June 2024 · filed 10 June 2024
- was granted 30,967 shares of Pacira BioSciences (a derivative holding)SEC Form 411 October 2023Stock Option (Right to Buy) · traded 6 October 2023 · filed 11 October 2023
- was granted 114,445 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 48 February 2023Stock Option (Right to Buy) · traded 6 February 2023 · filed 8 February 2023
- was granted 29,083 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 48 February 2023Restricted Stock Units · traded 6 February 2023 · filed 8 February 2023
- exercised options over 19,210 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 412 September 2022Stock Option (Right to Buy) · traded 8 September 2022 · filed 12 September 2022
- exercised options over 19,210 shares of Cerevel Therapeutics HoldingsSEC Form 412 September 2022Common Stock · traded 8 September 2022 · filed 12 September 2022
- ▼ sold on the open market 19,210 shares of Cerevel Therapeutics HoldingsSEC Form 412 September 2022Common Stock · traded 8 September 2022 · filed 12 September 2022
- exercised options over 9,605 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 424 August 2022Stock Option (Right to Buy) · traded 22 August 2022 · filed 24 August 2022
- exercised options over 9,605 shares of Cerevel Therapeutics HoldingsSEC Form 424 August 2022Common Stock · traded 22 August 2022 · filed 24 August 2022
- ▼ sold on the open market 9,605 shares of Cerevel Therapeutics HoldingsSEC Form 424 August 2022Common Stock · traded 22 August 2022 · filed 24 August 2022
- exercised options over 9,606 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 417 August 2022Stock Option (Right to Buy) · traded 15 August 2022 · filed 17 August 2022
- exercised options over 9,606 shares of Cerevel Therapeutics HoldingsSEC Form 417 August 2022Common Stock · traded 15 August 2022 · filed 17 August 2022
- ▼ sold on the open market 9,606 shares of Cerevel Therapeutics HoldingsSEC Form 417 August 2022Common Stock · traded 15 August 2022 · filed 17 August 2022
- exercised options over 38,424 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 49 August 2022Stock Option (Right to Buy) · traded 5 August 2022 · filed 9 August 2022
- exercised options over 19,211 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 49 August 2022Stock Option (Right to Buy) · traded 8 August 2022 · filed 9 August 2022
- exercised options over 38,424 shares of Cerevel Therapeutics HoldingsSEC Form 49 August 2022Common Stock · traded 5 August 2022 · filed 9 August 2022
- ▼ sold on the open market 38,424 shares of Cerevel Therapeutics HoldingsSEC Form 49 August 2022Common Stock · traded 5 August 2022 · filed 9 August 2022
- exercised options over 19,211 shares of Cerevel Therapeutics HoldingsSEC Form 49 August 2022Common Stock · traded 8 August 2022 · filed 9 August 2022
- ▼ sold on the open market 9,606 shares of Cerevel Therapeutics HoldingsSEC Form 49 August 2022Common Stock · traded 8 August 2022 · filed 9 August 2022
- ▼ sold on the open market 9,605 shares of Cerevel Therapeutics HoldingsSEC Form 49 August 2022Common Stock · traded 8 August 2022 · filed 9 August 2022
- was granted 120,310 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 411 February 2022Stock Option (Right to Buy) · traded 9 February 2022 · filed 11 February 2022
- was granted 461,065 shares of Cerevel Therapeutics Holdings (a derivative holding)SEC Form 43 June 2021Stock Option (Right to Buy) · traded 1 June 2021 · filed 3 June 2021
- was granted 80,971 shares of scPharmaceuticals (a derivative holding)SEC Form 419 January 2018Stock Option (Right to Buy) · traded 17 January 2018 · filed 19 January 2018
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.